Overview
Status
Active
Registry date
2014-01-24
Share capital
60,600.00 PLN
Registered address
Konarskiego 42/13, 30-046 Kraków, Poland
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed.
- 2025not filed
- 202403/07/2025
- 202301/07/2024
- 202204/07/2023
- 202101/03/2022
- 202002/09/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
Revenue
This companyUSD 2.15kMedianUSD 55.24kAverageUSD 2.71m
Net profit
This companyUSD 1.62kMedianUSD -1.27kAverageUSD -91.85k
Operating costs
This companyUSD 229.27MedianUSD 65.85kAverageUSD 2.66m
Assets
This companyUSD 246.44kMedianUSD 133.19kAverageUSD 3.03m
Industry
Authorized Representatives
Sławomir Henryk Gołda – Management Board Member
Michał Stanisław Korostyński – President of the Management Board
Marcin Piechota – Vice President of the Management Board
Manner of representation
To make declarations of will concerning the rights and obligations of the company and to sign documents on behalf of the company, the President of the Management Board is authorized in the case of a one-person management board, or two members of the management board in any other case.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Sławomir Henryk Gołdaage 47 | 106 | $2,863.32 | 17.4917% |
Michał Stanisław Korostyńskiage 48 | 212 | $5,726.63 | 34.9835% |
Marcin Piechotaage 45 | 212 | $5,726.63 | 34.9835% |
Klaudia Elżbieta Szklarczyk Smolanaage 40 | 76 | $2,052.94 | 12.5413% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| MedappS.A. | $3,351,163.61 | medapp.pl | ||
| SkinlabP.S.A. | $1,797,229.06 | skinlab.pl | ||
| EIT Rawmaterials Clc Eastsp. z o.o. | $1,795,803.10 | eitrawmaterials.eu | ||
| COS LabP.S.A. | $1,028,123.83 | coslab.pl | ||
| IntelliseqS.A. | $111,419.60 | intelliseq.pl | ||
| Przedsiębiorstwo Wielobranżowe Genezasp. z o.o. | $54,163.54 | geneza.eu | ||
| Medtransfersp. z o.o. | $21,666.01 | codete.com | ||
| Oncotherics PolandS.A. | $7,565.33 | oncotherics.com | ||
| Fusiomicasp. z o.o. | $5,263.98 | fusiomica.com | ||
| Ncage TherapeuticsS.A. | $29.14 | ncage.org |
Change history
| Date | Event | |
|---|---|---|
| 2021-02-09 | Business resumed | |
| 2020-03-12 | PKD change (Removed: 15 codes) | |
| 2018-09-06 | Business suspended | |
| 2018-05-18 | Share capital increase (53,000.00 PLN → 60,600.00 PLN) | |
| 2018-02-12 | Business resumed |
FAQ
The main business activity of Nextseq focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on January 24, 2014.
The headquarters is located at: Konarskiego 42, 30-046 Kraków.
The share capital of the company is PLN 60,600 (approx. $16,370).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
In 2024, the company generated total revenue of $2,149, representing a decrease of 8.3% compared to 2023.
Yes, in 2024 the company was profitable, achieving a net profit of $1,622, meaning the company decreased its profit by 24.3%.
The largest operating cost category falls under external services. This category amounted to $229 in 2024, representing 100% of all operating expenses.
Last updated: 2026-04-06